

FCRL6 antibody - middle region

Rabbit Polyclonal Antibody Catalog # Al12431

Specification

FCRL6 antibody - middle region - Product Information

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Calculated MW WB <u>Q6DN72</u> <u>NM_001004310</u>, <u>NP_001004310</u> Human Human Rabbit Polyclonal 48kDa KDa

FCRL6 antibody - middle region - Additional Information

Gene ID 343413

Alias Symbol FLJ16056, FcRH6 Other Names Fc receptor-like protein 6, FcR-like protein 6, FcRL6, Fc receptor homolog 6, FcRH6, IFGP6, FCRL6, FCRH6

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-FCRL6 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

FCRL6 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.

FCRL6 antibody - middle region - Protein Information

Name FCRL6

Synonyms FCRH6

Function

Acts as a MHC class II receptor (PubMed:20519654). When stimulated on its own, does not play a role in cytokine production or the release of cytotoxic granules by NK cells and cytotoxic CD8(+) T cells (PubMed:17213291, PubMed:18991291). Does not act as an Fc receptor (PubMed:<a href="http://www.uniprot.org/citations/18991291"



target="_blank">18991291).

Cellular Location Cell membrane; Single-pass type I membrane protein

Tissue Location

Expressed by cytolytic cells including NK cells, effector and effector-memory CD8(+) T-cells, and a subset of NKT cells (at protein level) (PubMed:17213291, PubMed:18991291, PubMed:20933011) Also expressed in gamma delta T cells and in a rare subset of effector CD4(+) T-cells (at protein level) (PubMed:18991291). Expressed in spleen, skin, peripheral blood leukocytes, liver, lung, bone marrow, small intestine and placenta (PubMed:20933011). Expression among T- cells is greatly expanded in HIV-1 infected individuals, and includes not only effector and effector-memory CD8(+) T-cells but also populations of CD4(+) T-cells (PubMed:17213291, PubMed:20933011) Expression among CD8(+) T-cells and NK cells is expanded in individuals with chronic lymphocytic leukemia (CLL) but is reduced in PBMCs from patients with acute (AML), chronic myeloid leukemia (CML) and non- Hodgkin's lymphoma (PubMed:18991291, PubMed:20933011). Expression is higher in PBMCs and/or CD3(+) cells of patients with autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and idiopathic thrombocytopenia purpura (ITP) (PubMed:20933011). In contrast, expression in CD3(+) cells from patients with lupus anticoagulans (LA) is higher (PubMed:20933011)

FCRL6 antibody - middle region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

FCRL6 antibody - middle region - Images

